665.54MMarket Cap-3160P/E (TTM)
9.3900High8.7800Low988.70KVolume9.1500Open9.1200Pre Close9.06MTurnover1.71%Turnover RatioLossP/E (Static)71.87MShares12.220052wk High3.39P/B535.60MFloat Cap2.410052wk Low--Dividend TTM57.84MShs Float86.5500Historical High--Div YieldTTM6.69%Amplitude2.1200Historical Low9.1600Avg Price1Lot Size
Mind Medicine Stock Forum
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
NEWS
MindMed Reports First Quarter 2024 Financial Results and Business Updates
MindMed received Breakthrough Therapy Designation (BTD) from the FDA for MM120 in the treatment of GAD in adults, after positive Phase 2b results showing statistically significant activity through 12 weeks.
The Company has a strong financial position with $252.3 million in cash and cash equivalents as of March 31, 2024, sufficient to fund operations into 2026.
MindMed is on track to begin its ...
bought position at 2.60🧠 said it was going to 17.0+ by end of the year. Its half way 💎
now my $Cybin(CYBN.US)$ and $ATAI Life Sciences(ATAI.US)$ are setting up for take off also. 🚀
Women's Day I hope for flowers 🌺
No comment yet